Artwork

Content provided by Karger Publishers. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karger Publishers or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

S1 E7 - Dr Shaheenah Dawood – ESMO 2022 – Clinical Trial Updates in Breast Cancer Management

13:39
 
Share
 

Manage episode 407348227 series 3559566
Content provided by Karger Publishers. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karger Publishers or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Welcome to the second episode in a three-part special live from ESMO 2022. In this episode focused on breast cancer, we speak with Dr Shaheenah Dawood, a practicing medical oncologist from Dubai, United Arab Emirates. Dr Dawood discusses the MONARCH3 trial – its background, recent findings and how it differs from the MONARCHER trial. Coverage is also given to the presentations on oral selective estrogen receptor downregulators (SERDs) as a treatment option for breast cancer patients.

For additional coverage and conference highlights in Oncology please visit https://www.karger.com/SubjectArea/Oncology/oncology-conference-highlights

For more podcast episodes from Karger please visit https://www.karger.com/podcasts

This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.

  continue reading

17 episodes

Artwork
iconShare
 
Manage episode 407348227 series 3559566
Content provided by Karger Publishers. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karger Publishers or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Welcome to the second episode in a three-part special live from ESMO 2022. In this episode focused on breast cancer, we speak with Dr Shaheenah Dawood, a practicing medical oncologist from Dubai, United Arab Emirates. Dr Dawood discusses the MONARCH3 trial – its background, recent findings and how it differs from the MONARCHER trial. Coverage is also given to the presentations on oral selective estrogen receptor downregulators (SERDs) as a treatment option for breast cancer patients.

For additional coverage and conference highlights in Oncology please visit https://www.karger.com/SubjectArea/Oncology/oncology-conference-highlights

For more podcast episodes from Karger please visit https://www.karger.com/podcasts

This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.

  continue reading

17 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide